Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History APM

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics APM

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Aptorum Group Ltd Class A

APM
Current price
0.90 USD +0.0032 USD (+0.36%)
Last closed 0.96 USD
ISIN KYG6096M1069
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 6 858 009 USD
Yield for 12 month -76.36 %
1Y
3Y
5Y
10Y
15Y
APM
21.11.2021 - 28.11.2021

Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa; and RPIDD, a liquid biopsy rapid pathogen diagnostic which is in preclinical trial to treat pathogen molecular diagnostics. The company also develops SACT-COV19, a repurposed small molecule which is in preclinical trial for the treatment of coronavirus disease; SACT-2 and SACT-3; ALS-1, a small molecule which is in preclinical trial to treat bacterial infections caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus (MRSA); and ALS-2/3, a small molecule which is in preclinical trial for the treatment of gram+ve bacterial infections. In addition, it is developing NLS-1, which is in preclinical trial for the treatment of endometriosis; DLS-1+2, which is in preclinical trial to treat NSCLC with mutation; DLS-3, which is in preclinical trial to treat autoimmune disease; CLS-1, a macromolecule, which is in preclinical trial to treat obesity; and CLS-1 and CLS-3. Further, the company offers NativusWell DOI (NLS-2), a dietary supplement for women undergoing menopause; and provides management services. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Address: 17 Hanover Square, London, United Kingdom, W1S 1BN

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

80.00 USD

P/E Ratio

Dividend Yield

Financials APM

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures APM

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

Last Year

+431 378 USD

Current Quarter

Last Quarter

Current Year

-255 000 USD

Last Year

+10 566 USD

Current Quarter

Last Quarter

-255 000 USD
EBITDA -2 194 206 USD
Operating Margin TTM
Price to Earnings
Return On Assets TTM -8.33 %
PEG Ratio
Return On Equity TTM -30.62 %
Wall Street Target Price 80.00 USD
Revenue TTM
Book Value 3.77 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -100.00 %
Dividend Yield
Gross Profit TTM 5 251 USD
Earnings per share -0.78 USD
Diluted Eps TTM -0.78 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin

Stock Valuation APM

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 31.22
Price Sales TTM 23.35
Enterprise Value EBITDA -0.45
Price Book MRQ 0.31

Technical Indicators APM

For 52 Weeks

0.46 USD 4.74 USD
50 Day MA 0.98 USD
Shares Short Prior Month 59 563
200 Day MA 1.15 USD
Short Ratio 0.99
Shares Short 84 548
Short Percent 2.48 %